Overview:

Novel coronavirus SARS-CoV-2 has caused the pandemic of the respiratory diseases (COVID-19) around the world since 2020 (1). The spike glycoprotein (S) of coronavirus, a type I transmembrane protein containing two subunits, S1 and S2 is known to bind with host cells through the interaction with angiotensin-converting enzyme 2 (ACE2) and facilitate viral entry into the host cell (2). A variant of SARS-CoV-2 carrying A222V mutation in the spike protein, also designated as lineage B.1.177, originated in Spain and then spread rapidly across Europe. As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (3).

Gene Aliases:

2019-nCoV s1, SARS-CoV-2 spike S1, SARS-CoV-2 S1, novel coronavirus spike s1, nCov spike s1, coronavirus spike S1.

Genebank Number:

MN908947

Formulation:

Recombinant protein stored in 50mM sodium phosphate, pH 7.5, 300mM NaCl, 150mM imidazole.

References:

1. Zhou P, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270-89. 2. Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. Nature. 2020, 581:215-220. 3. Harvey WT, et al: SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev. Microbiol. 2021, 19:409–424.